On September 28, 2021 Admera Health, a precision-medicine company and genetics laboratory, reported that it has engaged Back Bay Life Science Advisors, a strategic advisory and investment banking firm, to explore strategic alternatives for its pharmacogenomics and clinical services business as part of a company-wide strategic review (Press release, Admera Health, SEP 28, 2021, View Source [SID1234590542]). Admera offers the most comprehensive clinical PGx test in the industry, covering 62 genes, over 270 medications, and over 20 therapeutic areas, including: psychiatry, cardiology, pain management, and oncology. Admera Health’s clinical services portfolio is built on a strong foundation of next-generation sequencing (NGS) and data analysis capabilities.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The company’s current PGx and clinical services product portfolio consists of:
PGxOne Plus is a 62-gene pharmacogenomics test that provides insight into how patients may respond to certain medications based on DNA variants that affect pharmacokinetics and pharmacodynamics
RxVision is a secure, online digital platform that delivers PGx test results to providers and offers a complete PGx assessment with the gene-drug interactions aligning with the FDA sources and guidelines from professional organizations. The product is accessible on web-based browsers, as well as iOS and Android mobile devices, obviating the need for complicated integration with electronic medical record systems
OncoGxOneis a comprehensive 364-gene Next Generation Sequencing assay for profiling all solid tumor types. Input includes both DNA and RNA for optimal fusion detection. The product compliments Admera Health’s suite of NGS tests, spanning the continuum of cancer patient care
The company has also capitalized on its infrastructure by partnering with other domain experts to expand its product offering, notably with its Cardiovascular Test Portfolio.
"We are proud of the significant commercial value we have built in our pharmacogenomics products and are looking to select a strategic partner with additional scale and resources to realize their full potential," said Jeffrey Mitchell, interim CEO of Admera Health.
The company will continue to own and operate its biopharma services business, providing genomics and bioinformatics services in a CAP-accredited CLIA certified laboratory for researchers working on projects ranging from exploratory to clinical.